top of page
資產 21_3x.png
資產 5_3x.png

ABOUT US

BACKGROUND

資產 3_3x.png

HKG Epitherapeutics Inc. was founded in 2016 by Prof. Moshe Szyf, a world pioneer in the exciting and rapidly emerging science of Epigenetics.

A Hong Kong company, dedicated to harnessing the untapped power and possibilities of Epigenetics (with its research and diagnostic lab in Hong Kong), HKG Epithehrapeutics is planning to expand operations by establishing “next generation” genetic diagnostic labs in several countries.

資產 3_3x.png

MISSION

With an emphasis on the evolving markets in Euro -Asia and our immediate focus on tests, prevention and early treatment for common diseases such as cancer, our mission is to positively impact the health care, well-being, quality of life and promoting healthy aging for large populations of people, worldwide.

Simply stated, the science of Epigenetics centers on DNA Methylation (a simple biochemical process) that changes a mark on your DNA when cancer or other catastrophic diseases may develop.

We also help researchers advance the clinical study of Epigenetics by providing the state of art DNA methylation analysis services.

資產 22_3x.png

FOCUS ON PREVENTION THE CHALLENGE

We need to develop tools that detect disease early that are:

資產 4_3x.png
資產 5_3x.png
資產 4_3x.png
資產 5_3x.png

Accurate

Cost
Effective

High
throughput

Could be 
used in wide
geographic areas

資產 5_3x.png

While the company is new, Szyf’s three decades of ground-breaking research and cutting-edge innovations in Epigenetics  -  how it occurs and how it is passed from generation to generation  -  has already disrupted medical science with its potential to detect, diagnose, prevent or curediseases.

HKG Epitherapeutics believes the ability to measure and diagnose these changes in DNA will not only revolutionize the impact on fighting disease but on regulating our critical cardiovascular, neurological, reproductive, and detoxification systems as well.​

We believe that integrating our novel diagnostics into these developing markets will greatly affect the quality of health care for the people of these countries. We are interested in building diagnostic licensing partnerships in this area, as they become available.

We invite you to contact us for more information. Join our mission to be a major force in theexplosive new science of Epigenetics by becoming a partner and an influencer in global healthcare.

HEADQUARTERS

資產 9_3x.png
shutterstock_16724935_edited.jpg

Research and
Development

Hong Kong

  - Developing the “platform”

  - Developing “Next Generation”

  - Automation

  - Global clinical trials

  - Developing the HKG and global markets.

  - Early detection screening

HKG epi THERAPEUTICS LTD LaboratoryRECEIVES ACCREDITATION FROM COLLEGE OF AMERICAN PATHOLOGISTS

2022-02-03 / Press Releases

資產 10_3x.png
Hong Kong, January 12, 2022

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to HKG epiTherapeutics Ltd Laboratory, Hong Kong, based on results of recent on-site inspection as part of the CAP’s Accreditation Programs.

The accreditation for HKG epiTherapeutics Ltd Laboratory in 3/F Biotech Centre 2, 11 Science Park West Avenue Hong Kong and its Cervical cancer detection test using Next Generation sequencing technology.

HKG cervical cancer detection test in unique by detecting cancer in otherwise premalignant samples using next generation sequencing and DNA methylation, developed by HKG epitherapeutics in collaboration with McGill University in Montreal Canada.

The facility’s director, Carlos J. Ruiz, MD, was advised of this national recognition and congratulated for the excellence of the services being provided, HKG epiTherapeutics Ltd Laboratory is one of more than 8000 CAP-accredited facilities worldwide.

“It is an important milestone for our company translating our discoveries to excellence in delivery of highest quality early detection clinical tests to people of Hong Kong the US and globally said Prof Moshe Szyf, the founder of HKG epiTherapeutics Ltd.

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government’s own inspection program.

During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

Prof. Moshe Szyf, the founder of HKG Epitherapeutics, says: “ We thank the Accreditation Committee of the College of American Pathologists for its thorough review and for awarding HKG Epitherapeutics this important recognition of our excellence in clinical testing. We also congratulate our employees for their excellence and hard work leading us to this milestone. We aspire to provide the highest quality of clinical testing services.”

About HKG EPITHERAPEUTICS LTD

HKG Epitherapeutics was founded in 2016 by Prof. Moshe Szyf, a world pioneer in the exciting and rapidly emerging science of Epigenetics.

A Hong Kong company, dedicated to harnessing the untapped power and possibilities of Epigenetics (with its research and diagnostic lab in Hong Kong).
bottom of page